论文部分内容阅读
目的探讨尿激酶静脉溶栓治疗急性脑梗死患者的安全性及疗效。方法50例急性脑梗死患者,按入组顺序征得患者知情同意后分为两组,25例接受尿激酶100万单位静脉溶栓治疗,另25例为对照组。采用欧洲卒中量表评价神经功能恢复情况。结果溶栓组溶栓后24h、1d和7d的欧洲卒中量表分值增加明显,疗效显著优于对照组(P<0.05)。两组出血率相似,且均无死亡病例。结论尿激酶100万单位用于急性脑梗死发病12h内静脉溶栓治疗有效且比较安全。
Objective To investigate the safety and efficacy of intravenous thrombolytic therapy of urokinase in patients with acute cerebral infarction. Methods Fifty patients with acute cerebral infarction were divided into two groups according to the sequence of patients receiving informed consent and 25 patients received intravenous thrombolysis with urokinase 1 million and the other 25 patients as control group. Assessment of neurological recovery using the European Stroke Scale. Results The score of Stroke Scale increased significantly at 24h, 1d and 7d after thrombolysis in thrombolysis group, and the curative effect was better than that of control group (P <0.05). Bleeding rates were similar in both groups, with no deaths. Conclusions Urokinase 1 million units are effective and safe for intravenous thrombolysis within 12 hours of onset of acute cerebral infarction.